Track the Elicio Therapeutics, Inc. share price and the full insider trade history of the company, a listed issuer based in United States. Shares are quoted on the US market, under the oversight of SEC (Form 4). Market capitalisation: €83.8m. The latest transaction was disclosed on 3 February 2026 (Attribution). Among the most active insiders: DeMuth Peter. The full history is free.
9
Insider Decl.
n/a
Thresholds
€6m
1 ops.
Buy Volume
n/a
n/a
Sell Volume
19Σ signal
Buys €6mn/a Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
1,213,000 shares@ US$5.8125.1% of flowCommon StockSEC:0001209191-23-059683:0
Canonical exit: 21 Mar 2024 (T+90)
9 of 9 declarations
Acerca de Elicio Therapeutics, Inc.
Elicio Therapeutics, Inc. es una empresa biofarmacéutica centrada en el desarrollo de tratamientos inmunoterapéuticos para el cáncer. La empresa utiliza tecnología innovadora para mejorar las respuestas inmunitarias de los pacientes.